European Communities – Measures Affecting the Approval and Marketing of Biotech Products (WT/DS/291, 292, and 293)

The document provides technical and legal arguments to support the position that 'insufficient scientific evidence' under the SPS Agreement should be interpreted to include cases of high scientific uncertainty. It details the unpredictable nature of rDNA techniques, the lack of independent peer-reviewed data, and the potential for unintended toxic or environmental effects, asserting that these factors prevent adequate risk assessments and justify precautionary regulatory measures.

• The process of genetic modification using recombinant DNA (rDNA) technology is characterized by inherent imprecision and unpredictability, as techniques like particle bombardment and electroporation do not allow for control over the sequence, site, or number of transgene copies integrated into the host genome.
• Scientific assessments of GMO safety are often based on unpublished, non-peer-reviewed studies conducted by the developers themselves, with critical data frequently withheld from independent scientists and regulators as 'confidential business information' (CBI).
• There is significant uncertainty regarding the health impacts of novel proteins generated by GMOs, including potential autoimmune disorders, allergic reactions, and toxic effects, such as the eosinophilia myalgia syndrome linked to genetically modified bacteria used for tryptophan production.
• GMOs pose documented environmental risks, including the development of herbicide-resistant weeds and the potential for transgenic trait contamination of conventional and organic seed crops, which challenges the feasibility of co-existence schemes.
• The brief argues that 'insufficient scientific evidence' under Article 5.7 of the SPS Agreement should be interpreted to include situations where scientific uncertainty prevents an adequate risk assessment, thereby protecting a Member's right to determine its own appropriate level of protection.
• The precautionary principle, as reflected in the Cartagena Protocol on Biosafety and the 1992 Rio Declaration, establishes that a lack of full scientific certainty should not be used to postpone measures to prevent environmental degradation or adverse effects from GMOs.

APA

Center for International Environmental Law (2004). European Communities – Measures Affecting the Approval and Marketing of Biotech Products (WT/DS/291, 292, and 293). https://www.ciel.org/wp-content/uploads/2015/03/ECBiotech_AmicusBrief_2June04.pdf

Chicago

Center for International Environmental Law. European Communities – Measures Affecting the Approval and Marketing of Biotech Products (WT/DS/291, 292, and 293). 2004. https://www.ciel.org/wp-content/uploads/2015/03/ECBiotech_AmicusBrief_2June04.pdf.

Wikipedia

{{cite report |author=Center for International Environmental Law |title=European Communities – Measures Affecting the Approval and Marketing of Biotech Products (WT/DS/291, 292, and 293) |date=1 June 2004 |url=https://www.ciel.org/wp-content/uploads/2015/03/ECBiotech_AmicusBrief_2June04.pdf |access-date=23 October 2026 |via=Climate Insights Directory}}

BibTeX

@techreport{centerforinternationalenvironmentallaw2004european, author = {{Center for International Environmental Law}}, title = {{European Communities – Measures Affecting the Approval and Marketing of Biotech Products (WT/DS/291, 292, and 293)}}, institution = {Center for International Environmental Law}, year = {2004}, month = jun, url = {https://www.ciel.org/wp-content/uploads/2015/03/ECBiotech_AmicusBrief_2June04.pdf}, urldate = {2026-10-23}, note = {Indexed by Climate Insights Directory} }